OmniAb, Inc. (NASDAQ:OABI) Q4 2023 Earnings Conference Call March 20, 2024 4:30 PM ET

Company Participants

Kurt Gustafson - CFO
Matthew Foehr - President, CEO

Conference Call Participants

Puneet Souda - Leerink Partners
Joseph Pantginis - H.C. Wainright
Chad Wiatrowski - TD Cowen
Stephen Willey - Stifel
Jack Siedow - Craig-Hallum
Conor McNamara - RBC Capital Markets

Operator

Good afternoon, and welcome to OmniAb, Incorporated Fourth Quarter and Full Year 2023 Financial Results and Business Update Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

I would now like to turn the call over to Kurt Gustafson, OmniAb, Incorporated's Chief Financial Officer. You may begin. Thank you.

Kurt Gustafson

Thank you, operator, and good afternoon, everyone. As you said, this is Kurt Gustafson, and I want to thank you all for joining our fourth quarter and full year 2023 financial results conference call. There are slides to accompany today's prepared remarks, and they are available in the Investors section of our website at omniab.com.

Before we begin, I'd like to remind listeners that comments made during this call will include forward-looking statements within the meaning of the federal securities laws. These forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from any anticipated results. These forward-looking statements are qualified by the cautionary statements contained in today's press release and our SEC filings.

Importantly, this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, today, March 20, 2024. Except as required by law, OmniAb undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this call.

Joining me on the call today is Matt Foehr, OmniAb's President and CEO. During today's call, Matt and I will provide highlights on the company's operations, partner and technology updates and our recent financial results. At the conclusion of the prepared remarks, we'll open the call to questions.

With that, let me turn the call over to Matt.

Matthew Foehr

Thanks, Kurt, and good afternoon, everyone, and thanks for joining our fourth quarter and full-year 2023 conference call. As we kick off the call today, I'd like to mention that our clear mission here at OmniAb is to enable the rapid development of innovative therapeutics by pushing the frontiers of drug discovery technologies. We do this within a pure-play licensing business that is partnering-focused and that's designed to be efficient, scalable, highly leverageable, and that we believe is now poised for growth to meet what we see as an enduring and global need in the pharmaceutical industry.